GPI WEB CLIENT

Help | Comments | Logout

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers

Search Results - *158 Hits.*

Term	Occurrence
LEVODOPA/BI AND CARBIDOPA/BI	8
LEVODOPA/BI	16
CARBIDOPA/BI	12

Database: US, Japanese and European Patents

Refine Search:

#S2162

Search History

DB Name	Query	Hit Count	Set Name	Time
EPO	(same as L12)	8	L13	Mon Aug 31 14:31:39 1998
JPO	(same as L11)	0	L12	Mon Aug 31 14:31:38 1998
USPAT	#S2162	150	L11	Mon Aug 31 14:31:37 1998
USPAT	5387612	3	L10	Mon Aug 31 14:04:52 1998
USPAT	#L4	150	L9	Mon Aug 31 13:35:23 1998
USPAT	#L4	0	L8	Mon Aug 31 13:35:22 1998
EPO	#L6	8	L7	Mon Aug 31 13:32:27 1998
EPO	(same as L5)	8	L6	Mon Aug 31 13:32:18 1998
JPO	(same as L4)	0	L5	Mon Aug 31 13:32:18 1998
USPAT	LEVODOPA AND CARBIDOPA	150	L4	Mon Aug 31 13:32:17 1998
EPO	(same as L2)	16	L3	Mon Aug 31 13:32:07 1998
JPO	(same as L1)	2	L2	Mon Aug 31 13:32:06 1998
USPAT	LEVODOPA	378	L1	Mon Aug 31 13:32:06 1998

GPI WEB CLIENT

WO009212710A1 Aug. 6, 1992 L7: 2 of 8

ORALLY ADMINISTERABLE DRUGS FOR THE TREATMENT OF CENTRAL DOPAMINE DEFICIENCY CONDITIONS

INVENTOR: WENZEL, UDO (DE)
WEBER, GUENTHER (DE)
METZNER, JUERGEN (DE)
DAERR, ALFRED (DE)
FREITAG, SABINE (DE)
FLOETHER, FRANK-ULRICH (CH)
ALBERT, FRANK-MICHAEL (DE)
HAASE, MARGIT (DE)
LEISTNER, EDITH (DE)
APPLICANT: ISIS CHEMIE GMBH (DE)

APPL NO: DE 09200043
DATE FILED: Jan. 23, 1992
PRIOR-AP: DE 04101873A Jan. 23, 1991
INT-CL: A61K9/16; A61K9/20; A61K31/195
EUR-CL: A61K9/16; A61K9/20; A61K31/195

ABSTRACT:

The invention concerns an orally administerable drug formulation and a method of preparing it, in which the drugs **levodopa** and **carbidopa** are embedded in defined proportions in a hydrophilic substrate consisting of a mixture of poly(vinyl alcohol) polymers of different vinyl acetate content and non-toxic auxiliaries. This formulation considerably increases the effectiveness of the treatment of central dopamine deficiency conditions, in particular in Parkinson's disease, by ensuring that therapeutically effective blood values are maintained in the release phase.

GPI WEB CLIENT

EP000451484A1 Oct. 16, 1991 L7: 3 of 8

Deprenyl/L-dopa/ **carbidopa** pharmaceutical composition.

INVENTOR: BRZECZKO, ALBERT WALTER (US)
NIBBELINK, DONALD WILFRED (US)
MOLLICA, JOSEPH A (US)
APPLICANT: DU PONT MERCK PHARMA (US)
APPL NO: EP 91102994
DATE FILED: Feb. 28, 1991
PRIOR-AP: US 50696790A Feb. 28, 1990
INT-CL: A61K31/195
EUR-CL: A61K31/195

ABSTRACT:

Disclosed are pharmaceutical combination products useful for the treatment of Parkinson's disease. These products are based on a combination of active ingredients which are **carbidopa** , **levodopa** , deprenyl in a pharmaceutical carrier, preferably a carrier wherein one or more of the active ingredients are in a sustained release oral dosage formulation.

GPI WEB CLIENT

US004983400A Jan. 8, 1991 L7: 4 of 8

Controlled release combination of **carbidopa** / **levodopa**

INVENTOR: DEMPSKI, ROBERT E (US)
SCHOLTZ, EDWARD C (US)
NIBBELINK, DONALD W (US)
REINES, SCOTT A (US)
APPLICANT: MERCK & CO INC (US)
APPL NO: US 44422289
DATE FILED: Dec. 1, 1989
PRIOR-AP: US 44422289A Dec. 1, 1989
INT-CL: A61K9/22; A61K9/26; A61K31/78
EUR-CL: A61K9/20; A61K9/20; A61K31/19; A61K31/195

ABSTRACT:

A matrix or monolithic drug delivery system for the controlled release of **carbidopa** and **levodopa** consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard **carbidopa** / **levodopa** combination presen employed.

GPI WEB CLIENT

Help | Comments | Logout

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers

Search Results - *Records 1 through 8 of 8 returned.*

Generate Result Set

1. WO009513803A1, May 26, 1995, BLOCKING INDUCTION OF TETRAHYDROBIOPTERIN TO BLOCK INDUCTION OF NITRIC OXIDE SYNTHESIS; GROSS, STEVEN S,
INT-CL: [6] A61K31/195; [6] A61K31/495
EUR-CL: A61K31/40; A61K31/505; A61K31/505

1. ☐ Front | Citation | Pub | Cls

2. WO009212710A1, Aug. 6, 1992, ORALLY ADMINISTERABLE DRUGS FOR THE TREATMENT OF CENTRAL DOPAMINE DEFICIENCY CONDITIONS; WENZEL, UDO (DE), et al.,
INT-CL: A61K9/16; A61K9/20; A61K31/195
EUR-CL: A61K9/16; A61K9/20; A61K31/195

2. ☐ Front | Citation | Pub | Cls

3. EP000451484A1, Oct. 16, 1991, Deprenyl/L-dopa/ **carbidopa** pharmaceutical composition.; BRZECZKO, ALBERT WALTER (US), et al.,
INT-CL: A61K31/195
EUR-CL: A61K31/195

3. ☐ Front | Citation | Pub | Cls

4. US004983400A , Jan. 8, 1991, Controlled release combination of **carbidopa** / **levodopa** ; DEMPSKI, ROBERT E (US), et al.,
INT-CL: A61K9/22; A61K9/26; A61K31/78
EUR-CL: A61K9/20; A61K9/20; A61K31/19; A61K31/195

4. ☐ Front | Citation | Pub | Cls

5. US004900755A , Feb. 13, 1990, Controlled release combination of **carbidopa** / **levodopa** ; DEMPSKI, ROBERT E (US), et al.,
INT-CL: A61K9/20; A61K9/22; A61K9/26
EUR-CL: A61K9/20; A61K9/20; A61K31/19; A61K31/195

5. ☐ Front | Citation | Pub | Cls

6. EP000320051A1, Jun. 14, 1989, Controlled release combination of **carbidopa** / **levodopa** .; DEMPSKI, ROBERT E, et al.,
INT-CL: A61K9/22; A61K9/26; A61K31/19; A61K31/195
EUR-CL: A61K31/19; A61K31/195; A61K9/20; A61K9/20

6. ☐ Front | Citation | Pub | Cls

7. EP000282206A1, Sep. 14, 1988, Arylcyclobutylalkylamine-derivative for the treatment of Parkinson's disease.; REES, JOHN ANDREW,
INT-CL: A61K31/135; A61K31/195; A61K31/215; A61K31/33; A61K31/395
EUR-CL: A61K31/135; A61K31/195; A61K31/215; A61K31/33; A61K31/395; A61K31/15; A61K31/215; A61K31/33; A61K31/395

7. ☐ Front | Citation | Pub | Cls

8. EP000253490A1, Jan. 20, 1988, Controlled release combination of **carbidopa** / **levodopa** .; DEMPSKI, ROBERT E, et al.,
INT-CL: [4] A61K9/22
EUR-CL: A61K31/195; A61K9/20; A61K9/20

8. ☐ Front | Citation | Pub | Cls

Generate Result Set

Term	Occurrence
LEVODOPA/BI AND CARBIDOPA/BI	8
LEVODOPA/BI	16
CARBIDOPA/BI	12

Show 10 More Patents Starting At: 1 Display Format: B

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers